Related Experiment Videos
SERMs: current status and future trends
Karla C Morello1, Gregory T Wurz, Michael W DeGregorio
1Department of Internal Medicine, Division of Hematology/Oncology, Cancer Center, University of California, Davis, 4501 X Street Room 3016, Sacramento, CA 95817, USA.
Critical Reviews in Oncology/Hematology
|July 6, 2002
Summary
Selective estrogen receptor modulators (SERMs) offer tissue-specific effects, acting as agonists or antagonists. These compounds are crucial for treating breast cancer, osteoporosis, and cardiovascular disease.
Area of Science:
- Pharmacology
- Endocrinology
- Oncology
Background:
- Selective estrogen receptor modulators (SERMs) exhibit tissue-specific estrogen receptor (ER) activity, functioning as agonists or antagonists.
- SERMs are investigated for treating and preventing breast cancer, osteoporosis, and cardiovascular disease.
Purpose of the Study:
- To review the clinical applications and development of SERMs.
- To highlight the therapeutic potential and side effect profiles of existing and novel SERMs.
Main Methods:
- Literature review of SERMs, including tamoxifen, toremifene, and raloxifene.
- Analysis of clinical data on SERM efficacy and safety.
Main Results:
- Tamoxifen and toremifene are used for breast cancer, benefiting bone and lipids but stimulating the uterus.
- Raloxifene treats osteoporosis, with bone and lipid benefits, but without uterine stimulation.
- All three approved SERMs are linked to venous thromboembolism and hot flashes.
Conclusions:
- SERMs represent a vital therapeutic class for hormone-dependent diseases.
- Ongoing development of new SERMs aims to improve efficacy and safety profiles for various conditions.